

# 1 **Therapeutic effects of dipyridamole on COVID-19 patients with** 2 **coagulation dysfunction**

3 Xiaoyan Liu<sup>1#</sup>, Zhe Li<sup>2#</sup>, Shuai Liu<sup>1,3#</sup>, Zhanghua Chen<sup>4,5#</sup>, Jing Sun<sup>6#</sup>, Zhiyao Zhao<sup>4#</sup>, Yi-you  
4 Huang<sup>2#</sup>, Qingling Zhang<sup>6#</sup>, Jun Wang<sup>4</sup>, Yinyi Shi<sup>3</sup>, Yanhui Xu<sup>4</sup>, , Huifang Xian<sup>4</sup>, Rongli Fang<sup>4</sup>, Fan  
5 Bai<sup>5</sup>, Changxing Ou<sup>6</sup>, Bei Xiong<sup>1</sup>, Andrew M Lew<sup>7</sup>, Jun Cui<sup>8</sup>, Hui Huang<sup>9</sup>, Jincun Zhao<sup>6\*</sup>, Xuechuan  
6 Hong<sup>10,11\*</sup>, Yuxia Zhang<sup>4\*</sup>, Fuling Zhou<sup>1\*</sup>, and Hai-Bin Luo<sup>2\*</sup>

7 <sup>1</sup>Department of Hematology, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China

8 <sup>2</sup>School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510006, P. R. China

9 <sup>3</sup>Dawu County People's Hospital, Xiaogan City, 432826, China

10 <sup>4</sup>Guangzhou Institute of Pediatrics, Guangzhou Women and Children's Medical Center, State Key  
11 Laboratory of Respiratory Diseases, Guangzhou Medical University, Guangzhou, 510623, China

12 <sup>5</sup>Biomedical Pioneering Innovation Center (BIOPIC), School of Life Sciences, Peking University,  
13 Beijing, 100871, China

14 <sup>6</sup>Department of Allergy and Clinical Immunology, State Key Laboratory of Respiratory Diseases,  
15 National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory  
16 Health, The First Affiliated Hospital of Guangzhou Medical University. 151 Yanjiang Road,  
17 Guangzhou, 510120, China

18 <sup>7</sup>Walter and Eliza Hall Institute of Medical Research and Department of Microbiology &  
19 Immunology, University of Melbourne, Parkville, Vic, 3052, Australia

20 <sup>8</sup>School of Life Sciences, Sun Yat-sen University, Guangzhou, Guangdong, 510006, China

21 <sup>9</sup> Cardiovascular Department, The Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen,  
22 518000, China

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

23 <sup>10</sup>State Key Laboratory of Virology, College of Science, Innovation Center for Traditional Tibetan  
24 Medicine Modernization and Quality Control, Medical College, Tibet University, Lhasa, 850000,  
25 China

26 <sup>11</sup>Key Laboratory of Combinatorial Biosynthesis and Drug Discovery (MOE), Hubei Province  
27 Engineering and Technology Research Center for Fluorinated Pharmaceuticals, Wuhan University  
28 School of Pharmaceutical Sciences, Wuhan, 430071, China

29 **#Joint first authors.**

30 **\*Corresponding authors**

31 1) Prof. Hai-Bin Luo: School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou,  
32 510006, China. E-mail: [luohb77@mail.sysu.edu.cn](mailto:luohb77@mail.sysu.edu.cn)

33 2) Prof. Fuling Zhou: Department of Hematology, Zhongnan Hospital of Wuhan University, Wuhan,  
34 430071, China. E-mail: [zhoufuling@whu.edu.cn](mailto:zhoufuling@whu.edu.cn)

35 3) Prof. Yuxia Zhang: Guangzhou Institute of Pediatrics, Guangzhou Women and Children's Medical  
36 Center, State Key Laboratory of Respiratory Diseases, Guangzhou Medical University,  
37 Guangzhou, 510623, China. E-mail: [yuxia.zhang@gwcmc.org](mailto:yuxia.zhang@gwcmc.org)

38 4) Prof. Jincun Zhao: State Key Laboratory of Respiratory Diseases, Guangzhou Institute of  
39 Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou,  
40 510120, China. E-mail: [zhaojincun@gird.cn](mailto:zhaojincun@gird.cn)

41 5) Prof. Xuechuan Hong: State Key Laboratory of Virology, College of Science, Innovation Center  
42 for Traditional Tibetan Medicine Modernization and Quality Control, Medical College, Tibet  
43 University, Lhasa, 850000, China. E-mail: [xhy78@whu.edu.cn](mailto:xhy78@whu.edu.cn)

44  
45  
46

47 **Abstract:** The human coronavirus HCoV-19 infection can cause acute respiratory distress syndrome  
48 (ARDS), hypercoagulability, hypertension, extrapulmonary multiorgan dysfunction. Effective  
49 antiviral and anti-coagulation agents with safe clinical profiles are urgently needed to improve the  
50 overall prognosis. We screened an FDA approved drug library and found that an anticoagulant agent  
51 dipyridamole (DIP) suppressed HCoV-19 replication at an EC50 of 100 nM *in vitro*. It also elicited  
52 potent type I interferon responses and ameliorated lung pathology in a viral pneumonia model. In  
53 analysis of twelve HCoV-19 infected patients with prophylactic anti-coagulation therapy, we found  
54 that DIP supplementation was associated with significantly increased platelet and lymphocyte counts  
55 and decreased D-dimer levels in comparison to control patients. Two weeks after initiation of DIP  
56 treatment, 3 of the 6 severe cases (60%) and all 4 of the mild cases (100%) were discharged from the  
57 hospital. One critically ill patient with extremely high levels of D-dimer and lymphopenia at the time  
58 of receiving DIP passed away. All other patients were in clinical remission. In summary, HCoV-19  
59 infected patients could potentially benefit from DIP adjunctive therapy by reducing viral replication,  
60 suppressing hypercoagulability and enhancing immune recovery. Larger scale clinical trials of DIP  
61 are needed to validate these therapeutic effects.

62  
63 **Keyword:** Dipyridamole, HCoV-19, Pneumonia, Treatment, D-dimer

64  
65 **Introduction**

66 The novel coronavirus HCoV-19 (also known as SARS-CoV-2) outbreak had emerged from Wuhan,  
67 Hubei Province, China in December 2019.<sup>1,2</sup> As of February 24, there had been 77,787 confirmed  
68 COVID-19 cases including 2,666 deaths in China. Over 2,500 infections have also been reported in

69 28 other countries, such as Japan, South Korea, Italy, Singapore, Iran, Thailand, and U.S.A; this  
70 rapid spread threatens to become a pandemic. To date, no agents have been reported to be effective  
71 against this infection. Identification of readily available drugs for repurpose in COVID-19 therapy  
72 avail a relatively rapid way to clinical treatment.<sup>3</sup>

73  
74 HCoV-19, together with SARS-CoV and MERS-CoV, belong to the *Beta-coronavirus* genus, which  
75 are enveloped, positive-stranded RNA viruses with approximately 30,000 nucleotides.<sup>4,5</sup> Angiotensin  
76 I converting enzyme 2 (ACE2) is the receptor that engages the Spike surface glycoprotein of  
77 SARS-CoV and HCoV-19.<sup>6,7</sup> ACE2 is expressed in many organs, including the lung, heart, kidney,  
78 and intestine. Notably, in experimental models of SARS-CoV infection, Spike protein engagement  
79 decreases ACE2 expression and activates the renin-angiotensin system (RAS).<sup>6</sup> RAS activation  
80 promotes platelet adhesion and aggregation and increases the risk for pulmonary embolism,  
81 hypertension and fibrosis.<sup>8-11</sup> It also accelerates cardiac and kidney injury by increasing local  
82 angiotensin II concentrations.<sup>12-14</sup> Apart from affecting the classic RAS pathway, ACE2 deficiency in  
83 the intestine is associated with malnutrition and colonic inflammation.<sup>15</sup>

84  
85 Infection from SARS-CoV can result in severe lymphopenia, prolonged coagulation profiles, lethal  
86 acute respiratory distress syndrome (ARDS), watery diarrhea, cardiac disease and sudden death.<sup>9,16-18</sup>  
87 Many of these features have also been reported for COVID-19: prolonged coagulation profiles,  
88 elevated D-dimer levels, severe lymphopenia, ARDS, hypertension, and acute heart injury in  
89 ICU-admitted patients.<sup>2,19</sup> Given that angiotensin II levels were highly elevated in the HCoV-19  
90 infected patients,<sup>20</sup> RAS was likely activated in HCoV-19 infected patients, Thus, prophylactic  
91 anti-coagulation therapy should be considered for mollifying the multi-organ damage during severe  
92 COVID-19.

93

94 After viral entry to the host cells, the coronavirus messenger RNA is first translated to yield the  
95 polyproteins, which are subsequently cleaved by two viral proteinases, 3C-like protease (3CLP, aka  
96 nsp5 or Mpro) and papain-like protease (PLP, or nsp3), to yield non-structural proteins essential for  
97 viral replication.<sup>21</sup> Inhibitors that suppress the activity of these proteases may inhibit viral replication  
98 and offer a revenue for the HCoV-19 therapy.

99  
100 Dipyridamole (DIP) is an antiplatelet agent and acts as a phosphodiesterase (PDE) inhibitor that  
101 increases intracellular cAMP/cGMP.<sup>22</sup> Apart from the well-known antiplatelet function, DIP may  
102 provide additional therapeutic benefits to COVID-19 patients. First, published studies,<sup>23-28</sup> including  
103 clinical trials conducted in China,<sup>29-31</sup> have demonstrated that DIP has a broad spectrum antiviral  
104 activity, particularly efficacious against the positive-stranded RNA viruses.<sup>24</sup> Second, it suppresses  
105 inflammation and promotes mucosal healing.<sup>32</sup> Third, as a pan-PDE inhibitor, DIP may prevent  
106 acute injury and progressive fibrosis of the lung, heart, liver, and kidney.<sup>33</sup> Here we provide three  
107 levels of evidence advocating DIP as a therapy. *In silico and in vitro*, we demonstrated that DIP  
108 possessed anti- HCoV-19 effects. In a VSV-induced pneumonia model, we also confirmed that DIP  
109 elicited potent antiviral immunity and significantly improved the survival rate. In a small clinical  
110 cohort, we found that DIP adjunctive therapy led to increased circulating lymphocyte and platelet  
111 counts and lowered D-dimer levels, and markedly improved clinical outcomes.

112

## 113 **Methods**

### 114 **Free energy perturbation and surface plasmon resonance (SPR) assay**

115 We virtually screened an FDA-approved drug database using the HCoV-19 protease Mpro as a target  
116 and validated the binding affinity by the SPR assay. DIP (PubChem CID: 3108, Figure S1) was  
117 identified as a lead drug. In order to obtain the binding pattern and calculate the binding free energy

118 between DIP and Mpro, DIP was firstly docked onto Mpro by using Glide, and the optimal binding  
119 pose was further assessed by absolute binding free energy calculation with free energy perturbation.  
120 <sup>34</sup> The calculations were carried out in Gromacs 2019, and the thermodynamic cycle and procedure  
121 was similar to that used by Matteo et al.<sup>35</sup> In the calculation, the ligand electrostatic and van der  
122 Waals interactions were decoupled using a linear alchemical pathway with  $\Delta\lambda = 0.10$  for the van der  
123 Waals and  $\Delta\lambda = 0.20$  for electrostatic interactions. To add the restraints, 12  $\lambda$  values were used.  
124 Therefore, a total of 28 windows for complex and 16 windows for ligand systems were employed,  
125 and 4 ns simulations were performed for each window. The relative position restraints consist of one  
126 distance, two angles, and three dihedrals harmonic potentials with a force constant of 10 kcal/mol/Å<sup>2</sup>  
127 [rad<sup>2</sup>]. The distance and angles for the restraints were determined by the values of the last 2 ns of the  
128 4 ns preliminary MD simulations. The sampled  $\Delta U$  in the simulations were fitted by Gaussian  
129 algorithms and the free energy estimates were obtained by using the Bennet acceptance ratio (BAR)  
130 method.<sup>36</sup>

131

132 The pGEX4T1-Mpro plasmid was constructed (Atagenix, Wuhan) and transfected the E. coli strain  
133 BL21 (Codonplus, Stratagene). GST-tagged protein was purified by GST-glutathione affinity  
134 chromatography and cleaved with FXa. The purity of recombinant protein was greater than 95% as  
135 judged by SDS-PAGE. The binding of DIP to Mpro was measured by the Biacore 8K system (GE  
136 healthcare) at 25 °C. Mpro was immobilized on a CM5 chip surface via covalent linkage to Mpro  
137 N-terminus. First, the CM5 chip was activated using 1:4 *N*-hydroxysuccinimide  
138 (NHS)/1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) at the flow rate of 10  $\mu$ L/min for 7  
139 min. Then, Mpro (90  $\mu$ g/mL) in 10 mM acetate buffer (pH 4.5) was passed over separate flow cells

140 at 10  $\mu\text{L}/\text{min}$  for 3 min (1800 response units), which followed by a blocking step using ethanolamine  
141 (1 M, pH 8.5) at 10  $\mu\text{L}/\text{min}$  for 7 min. Binding studies were performed by passing 5-80  $\mu\text{M}$  of DIP  
142 over the immobilized Mpro at the flow rate of 30  $\mu\text{L}/\text{min}$  and the contact time was set to be 200 s. A  
143 sample volume of 120  $\mu\text{L}$  DIP in running buffer was injected into the flow cell and the bound ligand  
144 was washed by running buffer which contained 10 mM phosphate, 137 mM NaCl, 2.7 mM KCl, pH  
145 7.4, and 0.5% DMSO.

146

#### 147 **Fluorescent focus assay**

148 Vero E6 cells were seeded in 96-well plates and treated with different dosages of dipyridamole or  
149 chloroquine for an hour before infected with HCoV-19. After 24 hours of incubation, cells were  
150 fixed and permeabilized with Cytofix/Cytoperm (BD), incubated with a rabbit anti-HCoV-19  
151 nucleocapsid protein polyclonal antibody (Sino Biological), followed by a HRP-labelled goat  
152 anti-rabbit secondary antibody (Jackson). The foci were visualized by TRUEBlue reagent. Foci in  
153 infected cells were counted with a ELISPOT reader. Viral titers were calculated as foci forming units  
154 (FFU) per ml.

155

#### 156 **RNA extraction and quantitative real-time PCR**

157 Total cellular RNA was isolated by TRIzol reagent (Invitrogen) and reverse transcription was  
158 performed using a reverse transcription kit (Vazyme). We performed real-time PCR with SYBR  
159 Green qPCR Mix (GenStar). Data were normalized to the *RPL13A* gene and relative abundance of  
160 transcripts was calculated by the *Ct* models. Following primers were used for real-time PCR:

161 *IFN- $\beta$*  forward primer: 5'CAGCAATTTTCAGTGTTCAGAAGC3';

162 *IFN-β* reverse primer: 5'TCATCCTGTCCTTGAGGCAGT3';  
163 *ISG15* forward primer: 5' TCCTGGTGAGGAATAACAAGGG3';  
164 *ISG15* reverse primer: 5' GTCAGCCAGAACAGGTCGTC3';  
165 *IFIT1* forward primer: 5' TCAGGTCAAGGATAGTCTGGAG3';  
166 *IFIT1* reverse primer: 5' AGGTTGTGTATTCCCACACTGTA3'.  
167 *RPL13A* forward primer: 5'GCCATCGTGGCTAAACAGGTA3'  
168 *RPL13A* reverse primer: 5'GTTGGTGTTCATCCGCTTGC3'

169

## 170 **Immunoblotting**

171 Whole-cell extracts were eluted with 5×SDS Loading Buffer and then resolved by SDS-PAGE. The  
172 resolved protein bands were electro-transferred to polyvinylidene fluoride membranes for further  
173 antibody incubation and detection. The antibodies against TBK1 [TBK1/NAK (D1B4) Rabbit mAb  
174 #3504, Phospho-TBK1/NAK (Ser172) (D52C2) XP® Rabbit mAb #5483] and IRF3 [IRF-3 (D83B9)  
175 Rabbit mAb #4302, Phospho-IRF-3 (Ser386) (E7J8G) XP® Rabbit mAb #37829] were purchased  
176 from Cell Signaling Technology and anti-β-actin (A1978) were purchased from Sigma.

177

## 178 **VSV-induced viral pneumonia model**

179 C57/BL-6J mice were obtained from the Guangdong Medical Laboratory Animal Center. Six-week  
180 old female mice were intravenous injected with VSV (10<sup>8</sup> PFU/g) and followed with DIP (35 mg/kg;  
181 intraperitoneal injection, i.p; twice/day) treatment for 5 days. Survival curve was measured. Mice  
182 were sacrificed at Day 4 for histology examination by hematoxylin-eosin (H&E) staining. The study  
183 procedure was approved by Animal Ethics Committee of Guangzhou Medical University.



184

## 185 **Patients and study variables**

186 As of February 8, 2020, 124 confirmed COVID-19 cases had been identified from Zhongnan  
187 Hospital of Wuhan University (**Table S1**). All patients met the diagnostic criteria of "Diagnosis and  
188 Treatment Scheme of Novel Coronavirus–Infected Pneumonia (trial 6th)" formulated by the General  
189 Office of National Health Committee.<sup>37</sup> A retrospective review of the medical records of these  
190 patients was conducted to retrieve coagulation indexes and platelet parameters, including  
191 prothrombin time (PT), activated partial thromboplastin time (APTT), plasma fibrinogen (FIB),  
192 D-dimer, platelet (PLT) count, and mean platelet volume (MPV). Systemic inflammation was  
193 assessed according to the C-reactive protein (CRP), procalcitonin (PCT), and interleukin 6 (IL-6)  
194 levels.<sup>12</sup>

195

## 196 **Study design**

197 Patients were enrolled from the isolation ward in Dawu County People's Hospital, a medical  
198 treatment alliance of Zhongnan Hospital, Hubei province in China, from Jan 23, 2020 to Feb 22,  
199 2020 to determine the effect of DIP to improve the coagulation profile. The condition of the patients  
200 was monitored daily by attending physicians. Routine laboratory test of the coagulation variables,  
201 blood indexes, liver and kidney function indices, and chest CT were carried out before, during, and  
202 after the treatment. Clinical symptoms and laboratory data were independently validated by two  
203 independent investigators for assurance of data accuracy. The diagnosis of severe case was made if  
204 patients met any of the following criteria: (1) respiratory rate  $\geq 30$  breaths/min; (2) SpO<sub>2</sub>  $\leq 93\%$   
205 while breathing room air; (3) PaO<sub>2</sub>/FiO<sub>2</sub>  $\leq 300$  mmHg. A critically ill case was diagnosed if any of

206 the following criteria was met: (1) respiratory failure which requiring mechanical ventilation; (2)  
207 shock; (3) combined with other organ failure, need to be admitted to ICU. The Ethics Committee  
208 from Dawu County People's Hospital approved the study. All patients signed informed consents.

209

### 210 **Treatment procedures**

211 Anticoagulant therapy was provided via oral DIP tablets. The daily treatment protocol comprised of  
212 150 mg in three separate doses for seven consecutive days. All patients were monitored daily for  
213 possible adverse events. All patients received antiviral (ribavirin, 0.5g, Q12h), corticoid  
214 (methylprednisolone sodium succinate, 40 mg, qd), oxygen therapy, and nutritional support as  
215 necessary.

216

### 217 **Statistical analysis**

218 Statistical analyses and graphics production were performed using R v3.5.3 (Foundation for  
219 Statistical Computing) and GraphPad Prism 8. Categorical variables were described as frequencies or  
220 percentages, and continuous variables were shown as mean with standard deviation/error or median  
221 with interquartile range. Comparison for two independent groups was conducted using Student's *t*  
222 test (for normally distributed data) or Mann-Whitney test (for non-normally distributed data). *P*  
223 < 0.05 was considered statistically significant. Detailed descriptions of data comparison and  
224 statistical tests were specified in the figure legends.

225

226

227

## 228 **Results**

### 229 **DIP suppresses HCoV-19 replication in Vero E6 cells**

230 We virtually screened an FDA approved drug library and found that DIP bound to the HCoV-19  
231 protease Mpro (**Figure S1**). Hydrophobic and hydrogen bond (H-bond) interactions are the main  
232 driving forces for the binding between DIP and Mpro. According to the free energy perturbation  
233 calculation, the binding free energy of  $\Delta G_{\text{pred}}$  was -6.34 kcal/mol. An SPR assay was carried out to  
234 validate the *in silico* result. This has revealed that DIP bound to Mpro with an experimentally  
235 confirmed affinity of 34  $\mu\text{M}$  ( $K_{D,eq}$ ) (**Figure 1A-B**).

236

237 To demonstrate directly that DIP suppresses HCoV-19 replication, we measured the viral titers using  
238 a susceptible cell line, the Vero E6 cells. Chloroquine was used as a positive control.<sup>38,39</sup> Remarkably,  
239 at 0.1  $\mu\text{M}$  DIP suppressed more than 50% of HCoV-19 replication (**Figure 1C**). Human DIP  
240 administration can achieve a 3  $\mu\text{M}$  serum concentration.<sup>40</sup> Thus, therapeutic dosages of DIP may  
241 effectively suppress HCoV-19 replication in the infected patients. Notably, however, the  
242 dose-dependent suppressive effect of dipyridamole was less apparent in comparison to Chloroquine,  
243 which suggested that DIP may employ a different mode of suppression.

244

### 245 **DIP promotes type I interferon (IFN) responses and protect mice from viral pneumonia**

246 Published studies have shown that DIP possessed broad spectrum activity to a wide range of viruses,  
247 indicating that it may elicit antiviral immunity from the host cells. We examined these using two  
248 single-stranded RNA viruses (Sendai virus, SeV and Vesicular stomatitis virus, VSV), as well as  
249 intracellular poly (I:C) that stimulates the RIG-I and MDA5 mediated IFN immunity, in the human

250 lung epithelial cell line A549 cells.<sup>41,42</sup> Our results demonstrated that DIP (5  $\mu$ M) treatment  
251 significantly increased *IFNB*, *IFIT1*, and *ISG15* messenger RNA expression and promoted IFN- $\beta$   
252 secretion (**Figure 2A**) by increasing TBK1 and IRF3 phosphorylation (**Figure 2B**).

253

254 To validate the antiviral effects of DIP *in vivo*, we established a VSV-induced pneumonia model. DIP  
255 administration significantly prolonged the survival rate of VSV-infected mice (**Figure 2C**), and  
256 substantially alleviated pulmonary pathology (**Figure 2D**). Thus, therapeutic doses of DIP can elicit  
257 potent and broad-spectrum antiviral immunity to single-stranded RNA viruses.

258

### 259 **A remarkable improvement of coagulation profile in COVID-19 patients receiving DIP** 260 **adjunctive therapy**

261 To assess the coagulation profile, we first retrospectively analyzed a randomly collected cohort of  
262 124 COVID-19 patients (**Table S1**). Decreased platelet counts were observed in 25 (20.2%) patients,  
263 prolonged prothrombin time (PT) was observed in 77 (62.1%) patients, fibrinogen (FIB) levels were  
264 increased in 27 (21.8%) patients, and D-dimer levels were increased in 26 (21.0%) patients. This  
265 suggest that hypercoagulability is common in COVID-19 patients.

266

267 To evaluate DIP as a therapy to reduce the risk of hypercoagulability, 22 additional patients including  
268 10 control patients and 12 patients who received DIP were recruited. Baseline characteristics of the  
269 two groups were similar (**Table 1**). The average ages of the patients were 53 and 58 years in the DIP  
270 group and the control group, respectively. All patients manifested cough and most of them felt  
271 shortness of breath, and 60.0% patients had nausea and vomiting. Chest CT scan revealed bilateral

272 pneumonia in all patients. Comorbidities, including diabetes mellitus, cardiovascular and  
273 cerebrovascular diseases, were found in 4 and 5 of the patients from the DIP and control group,  
274 respectively. All patients received ribavirin, glucocorticoids, and oxygen therapy, but none received  
275 antifungal treatment. Other treatment included mechanical ventilation (16.7% vs 10.0%), antibiotics  
276 (33.3% vs 30.0%), and intravenous immunoglobulin (16.7% vs 20.0%) in the DIP group and the  
277 control group, respectively.

278

279 Two weeks after initiation of DIP treatment, 3 of the 6 severe cases (50%) and all 4 of the mild cases  
280 (100%) were discharged from the hospital. One of the critically ill patient with extremely high levels  
281 of D-dimer and lymphopenia at the time of receiving DIP passed away. All other patients were in  
282 clinical remission. In comparison, the discharge and remission rates of the mild and severe cases  
283 were inferior in the control patients (**Table 2**).

284

285 The baseline temperature was higher and the oxygenation status was worse in the DIP-treated group  
286 than those in the control group, however, temperature and oxygenation were stabilized in the mild  
287 and severe patients from both groups after one day of treatment (**Figure S2**). Furthermore, we  
288 observed a continuously increased trend in lymphocyte counts and significantly increased platelet  
289 numbers in patients receiving DIP treatment in comparison to the control group (**Figure 3A**). Given  
290 that lymphocytopenia and thrombocytopenia are common in the severe and critically ill patients,  
291 immune recovery may contribute to infection resolution in DIP-treated patients. It should be noted  
292 that 4 patients from the DIP-treatment group and 2 patients from the control group had increased  
293 baseline levels of D-dimer when they were admitted to the hospital (**Table 1**). We measured dynamic

294 changes in reference to the respective baseline levels for all patients, and found that the levels of  
295 D-dimer continuously rose in the control group, whereas they were decreased and stabilized in the  
296 DIP-treated group (**Figure 3A, Figure S2**).

297

298 We then examined the two critically ill patients who received DIP adjunctive therapy. A 70-year-old  
299 man with very low oxygen saturation and has suffered from hypoxia and multiorgan dysfunction at  
300 hospital administration has passed away. He had extremely high levels of D-dimer (16.2 mg/L) and  
301 very low lymphocyte count ( $0.37 \times 10^9/L$ ) at the time of receiving DIP adjunctive therapy. His  
302 oxygen saturation remained low and has unfortunately passed away 5 days since initiation of DIP  
303 treatment. In contrast, the other severely ill patient also had very low oxygen saturation and high  
304 D-dimer level (8.83 mg/L) at administration. His D-dimer level had gone up to as high as 15.72  
305 mg/L, but gradually declined to 3.69 mg/L following DIP adjunctive therapy. The patient has since  
306 been in clinical remission. This reinforces that high levels of D-dimer and low lymphocyte counts are  
307 associated with poor prognosis and suggest that that DIP treatment should be initiated before the  
308 progression to critical illness (**Figure 3B**).

309

310 All patients had chest CT scans and showed typical multiple patchy ground-glass shadows in the  
311 lungs before the treatment. In the DIP treated patients, the lesions had varied degree of absorption.  
312 Typical findings following DIP treatment was illustrated in one of the severe COVID-19 patient who  
313 had taken sequential CT scans (**Figure 4**).

314

315

## 316 Discussion

317 Despite the enormous threat of HCoV-19, no drugs have been claimed to be effective including the  
318 existing drugs used to treat other viruses. In reference to SARS-CoV- infection, we hypothesized that  
319 the HCoV-19 Spike protein engagement may activate RAS in the lung.<sup>6,43</sup> This hypothesis was  
320 supported by published clinical characteristics and biochemical indices of the severe and critically ill  
321 COVID-19 patients, who showed ARDS, hypertension, acute heart, kidney injury, and positive  
322 D-dimer results.<sup>2,19,20</sup> In searching for available anticoagulants, we focused on DIP because of its  
323 broad-spectrum antiviral, anti-inflammatory, and anti-fibrotic effects. We confirmed that DIP  
324 possessed potent antiviral immunity to single-stranded RNA viruses *in vitro*, and in a VSV-induced  
325 viral pneumonia model *in vivo*. Most importantly, a laboratory confirmed EC<sub>50</sub> of 0.1 μM to  
326 suppress HCoV-19 replication highly suggested that the therapeutic dosage of DIP may potentiate  
327 effective antiviral responses in infected patients . These findings are in concordance with the overall  
328 remarkable outcomes in patients receiving one week of DIP adjunctive therapy, seven of the twelve  
329 patients were discharged from the hospital and four achieved clinical remission.

330

331 We found that DIP adjunctive treatment was effective in preventing hypercoagulability if applied  
332 early in the severe COVID-19 patients. DIP treatment blunted the increase in D-dimer levels and  
333 increased circulating platelet and leucocytes counts, and thus was associated with overall remarkable  
334 clinical cure and remission rates. High levels of D-dimer closely correlated with pulmonary  
335 embolism,<sup>44</sup> vascular thrombosis, and renal dysfunction.<sup>45</sup> It is an important prognostic factor of  
336 whether ICU-patients may recover from severe infections.<sup>46,47</sup> As such, the antiviral,  
337 anti-inflammatory, and anti-hypercoagulability effects of DIP could reduce the risk of micro-vascular

338 thrombosis in HCoV-19 infected patients. This could in turn improve vascular circulation and restore  
339 vital functions of important organs such as heart and kidney.

340

341 In summary, we suggest anti-coagulant therapy for COVID-19 patients with early signs of elevated  
342 D-dimer levels. DIP is an attractive anti-coagulant adjunctive therapy due to its safe clinical profile  
343 as an anti-platelet agent. It also holds additional benefits as a pan-PDE inhibitor in eliciting  
344 broad-spectrum antiviral immunity, as well as anti-inflammatory and anti-fibrotic effects. Moreover,  
345 the wide availability, safety and affordability of DIP argue for further investigation into its  
346 therapeutic use in COVID-19, particularly in the event of its rapid spread into the developing  
347 countries.

348

#### 349 **Contributors**

350 JZ, XH, YZ, FZ, and HBL co-designed the study and co-led overall data interpretation. ZL led the  
351 virtual screening, YH led the SPR analysis, ZC, ZZ, JW, YX, JL, HX, RF, FB, CJ, HH, and CO also  
352 participated in study design and performed *in vivo* and *in vitro* studies. XL, SL, YS, BX, XH, and FZ  
353 led the clinical analysis. XL, SL, YS, BX, XH, and FZ participated in data collection. ZC  
354 participated in data analysis. XL, SL, and ZC produced the tables and figures. AML reviewed the  
355 manuscript. YZ and HBL drafted the manuscript with significant input from JZ, XH, and FZ. All  
356 authors interpreted the results and critically revised the manuscript for scientific content. All authors  
357 approved the final version of the Article.

358

359



360 **Declaration of interests**

361 HBL, ZL, and YYH report grants from National Key R&D Program of China (2017YFB0202600),  
362 National Natural Science Foundation of China (8152204 and 21877134), and philanthropy donation  
363 from individuals. XL, SL, YS, BX, XH, and FZ report grants from Taikang Insurance Group Co., Ltd  
364 and Beijing Taikang Yicai Foundation, and philanthropy donation from individuals. YZ and XX  
365 report grants from National Natural Science Foundation of China (91742109, 31770978, and  
366 81773674) and philanthropy donation from individuals during the conduct of the study. Other  
367 authors declare no competing interests.

368

369 **Funding** National Key R&D Program of China (2017YFB0202600), National Natural Science  
370 Foundation of China (91742109, 8152204, 31770978, 81773674, and 21877134), Taikang Insurance  
371 Group Co., Ltd and Beijing Taikang Yicai Foundation, and philanthropy donation from individuals.  
372 The funders had no roles in the design and execution of the study.

373

374 **Acknowledgments**

375 We cordially acknowledge Tencent Cloud, National Supercomputing centers in Guangzhou and  
376 Shenzhen, and SenseTime for providing HPC resources for virtual screening and free energy  
377 perturbation calculations. We cordially thank Prof. H. Ke at the University of North Carolina, Chapel  
378 Hill, for his help to improve our writing of this work.

379 **Reference:**

- 380 1. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel  
381 coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet* 2020.
- 382 2. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan,  
383 China. *Lancet* 2020.
- 384 3. Holshue ML, DeBolt C, Lindquist S, et al. First Case of 2019 Novel Coronavirus in the United States. *N Engl J*

- 385 *Med* 2020.
- 386 4. Chan JF, Kok KH, Zhu Z, et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus  
387 isolated from a patient with atypical pneumonia after visiting Wuhan. *Emerg Microbes Infect* 2020; **9**(1): 221-36.
- 388 5. Wu A, Peng Y, Huang B, et al. Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV)  
389 Originating in China. *Cell Host Microbe* 2020.
- 390 6. Kuba K, Imai Y, Rao S, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS  
391 coronavirus-induced lung injury. *Nat Med* 2005; **11**(8): 875-9.
- 392 7. Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications  
393 for virus origins and receptor binding. *Lancet* 2020.
- 394 8. Marshall RP. The pulmonary renin-angiotensin system. *Curr Pharm Des* 2003; **9**(9): 715-22.
- 395 9. Imai Y, Kuba K, Rao S, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. *Nature*  
396 2005; **436**(7047): 112-6.
- 397 10. Kalinowski L, Matys T, Chabielska E, Buczek W, Malinski T. Angiotensin II AT1 receptor antagonists inhibit  
398 platelet adhesion and aggregation by nitric oxide release. *Hypertension* 2002; **40**(4): 521-7.
- 399 11. Chung T, Connor D, Joseph J, et al. Platelet activation in acute pulmonary embolism. *J Thromb Haemost* 2007;  
400 **5**(5): 918-24.
- 401 12. Yamamoto K, Ohishi M, Katsuya T, et al. Deletion of angiotensin-converting enzyme 2 accelerates pressure  
402 overload-induced cardiac dysfunction by increasing local angiotensin II. *Hypertension* 2006; **47**(4): 718-26.
- 403 13. Oudit GY, Herzenberg AM, Kassiri Z, et al. Loss of angiotensin-converting enzyme-2 leads to the late  
404 development of angiotensin II-dependent glomerulosclerosis. *Am J Pathol* 2006; **168**(6): 1808-20.
- 405 14. Crackower MA, Sarao R, Oudit GY, et al. Angiotensin-converting enzyme 2 is an essential regulator of heart  
406 function. *Nature* 2002; **417**(6891): 822-8.
- 407 15. Hashimoto T, Perlot T, Rehman A, et al. ACE2 links amino acid malnutrition to microbial ecology and intestinal  
408 inflammation. *Nature* 2012; **487**(7408): 477-81.
- 409 16. Oudit GY, Kassiri Z, Jiang C, et al. SARS-coronavirus modulation of myocardial ACE2 expression and  
410 inflammation in patients with SARS. *Eur J Clin Invest* 2009; **39**(7): 618-25.
- 411 17. Peiris JS, Guan Y, Yuen KY. Severe acute respiratory syndrome. *Nat Med* 2004; **10**(12 Suppl): S88-97.
- 412 18. Peiris JS, Yuen KY, Osterhaus AD, Stohr K. The severe acute respiratory syndrome. *N Engl J Med* 2003; **349**(25):  
413 2431-41.
- 414 19. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel  
415 Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA* 2020.
- 416 20. Liu Y, Yang Y, Zhang C, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to  
417 viral loads and lung injury. *Sci China Life Sci* 2020.
- 418 21. Adedeji AO, Sarafianos SG. Antiviral drugs specific for coronaviruses in preclinical development. *Curr Opin*  
419 *Viro* 2014; **8**: 45-53.
- 420 22. Gresele P, Momi S, Falcinelli E. Anti-platelet therapy: phosphodiesterase inhibitors. *Br J Clin Pharmacol* 2011;  
421 **72**(4): 634-46.
- 422 23. Tonew E, Indulen MK, Dzeguze DR. Antiviral action of dipyridamole and its derivatives against influenza virus  
423 A. *Acta Viro* 1982; **26**(3): 125-9.
- 424 24. Fata-Hartley CL, Palmenberg AC. Dipyridamole reversibly inhibits mengovirus RNA replication. *J Virol* 2005;  
425 **79**(17): 11062-70.
- 426 25. Tenser RB, Gaydos A, Hay KA. Inhibition of herpes simplex virus reactivation by dipyridamole. *Antimicrob*  
427 *Agents Chemother* 2001; **45**(12): 3657-9.
- 428 26. Szebeni J, Wahl SM, Popovic M, et al. Dipyridamole potentiates the inhibition by 3'-azido-3'-deoxythymidine  
429 and other dideoxynucleosides of human immunodeficiency virus replication in monocyte-macrophages. *Proc Natl*

- 430 *Acad Sci U S A* 1989; **86**(10): 3842-6.
- 431 27. Kozhukharova MS, Slepishkin AN, Radeva Kh T, Lavrukhina LA, Demidova SA. [Evaluation of dipyridamole  
432 efficacy as an agent for preventing acute respiratory viral diseases]. *Vopr Virusol* 1987; **32**(3): 294-7.
- 433 28. Kuzmov K, Galabov AS, Radeva K, Kozhukharova M, Milanov K. [Epidemiological trial of the prophylactic  
434 effectiveness of the interferon inducer dipyridamole with respect to influenza and acute respiratory diseases]. *Zh*  
435 *Mikrobiol Epidemiol Immunobiol* 1985; (6): 26-30.
- 436 29. Xie H. Efficacy of dipyridamole in the treatment of 116 children with acute upper respiratory tract infections.  
437 *Chinese Journal of School Doctor* 2010; **24**(12): 921-.
- 438 30. Hu X, Wang X. Treatment of viral upper respiratory tract infection in children with dipyridamole. *Chinese*  
439 *Journal of Hospital Pharmacy* 1995; (9).
- 440 31. Sui Y. Clinical observation of 45 cases of upper respiratory tract infection treated with dipyridamole. *The*  
441 *Medical Forum* 2014; **000**(032): 4360-1.
- 442 32. Huang B, Chen Z, Geng L, et al. Mucosal Profiling of Pediatric-Onset Colitis and IBD Reveals Common  
443 Pathogenics and Therapeutic Pathways. *Cell* 2019; **179**(5): 1160-76 e24.
- 444 33. Insel PA, Murray F, Yokoyama U, et al. cAMP and Epac in the regulation of tissue fibrosis. *Br J Pharmacol* 2012;  
445 **166**(2): 447-56.
- 446 34. Li Z, Huang Y, Wu Y, et al. Absolute Binding Free Energy Calculation and Design of a Subnanomolar Inhibitor  
447 of Phosphodiesterase-10. *J Med Chem* 2019; **62**(4): 2099-111.
- 448 35. Aldeghi M, Heifetz A, Bodkin MJ, Knapp S, Biggin PC. Accurate calculation of the absolute free energy of  
449 binding for drug molecules. *Chem Sci* 2016; **7**(1): 207-18.
- 450 36. HBennett C. Efficient estimation of free energy differences from Monte Carlo data. *Journal of Computational*  
451 *Physics* 1976; **22**(2): 245-68.
- 452 37. Committee GOoNH. Diagnosis and treatment scheme of novel coronavirus-infected pneumonia (trial  
453 version 6). [Http://www.nhcgov.cn](http://www.nhcgov.cn) 2020.
- 454 38. Vincent MJ, Bergeron E, Benjannet S, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and  
455 spread. *Virology* 2005; **2**: 69.
- 456 39. Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel  
457 coronavirus (2019-nCoV) in vitro. *Cell Res* 2020.
- 458 40. Serebruany V, Sabaeva E, Booze C, et al. Distribution of dipyridamole in blood components among  
459 post-stroke patients treated with extended release formulation. *Thromb Haemost* 2009; **102**(3): 538-43.
- 460 41. Sumpter R, Jr., Loo YM, Foy E, et al. Regulating intracellular antiviral defense and permissiveness to hepatitis C  
461 virus RNA replication through a cellular RNA helicase, RIG-I. *J Virol* 2005; **79**(5): 2689-99.
- 462 42. Loo YM, Gale M, Jr. Immune signaling by RIG-I-like receptors. *Immunity* 2011; **34**(5): 680-92.
- 463 43. Imai Y, Kuba K, Penninger JM. The discovery of angiotensin-converting enzyme 2 and its role in acute lung  
464 injury in mice. *Exp Physiol* 2008; **93**(5): 543-8.
- 465 44. Kline JA, Garrett JS, Sarmiento EJ, Strachan CC, Courtney DM. Over-Testing for Suspected Pulmonary  
466 Embolism in American Emergency Departments: The Continuing Epidemic. *Circ Cardiovasc Qual Outcomes* 2020;  
467 **13**(1): e005753.
- 468 45. Schefold JC, Gerber JL, Angehrn MC, et al. Renal Function-Adjusted D-Dimer Levels in Critically Ill Patients  
469 With Suspected Thromboembolism. *Crit Care Med* 2020.
- 470 46. Zhou J, Mao W, Shen L, Huang H. Plasma D-dimer as a novel biomarker for predicting poor outcomes in  
471 HBV-related decompensated cirrhosis. *Medicine (Baltimore)* 2019; **98**(52): e18527.
- 472 47. Adekanmbi O, Lakoh S. A favorable outcome of dengue hemorrhagic fever despite poor prognostic indices: a  
473 case report with a mix of classic and unusual clinical and laboratory features. *Pan Afr Med J* 2019; **34**: 74.

<b>Table 1. Baseline characteristics of enrolled patients</b>		
<b>Variable</b>	<b>Dipyridamole group (n=12)</b>	<b>Control group (n=10)</b>
<b>General Characteristic</b>		
Age (yr) — mean±sd (range)	53±10 (32-69)	58±15 (23-74)
Gender— male no. / female no.	8 / 4	7 / 3
<b>Clinical variables</b>		
Cough— no. (%)	12 (100.0%)	10(100.0%)
Shortness of breath — no. (%)	9 (75.0%)	7(70.0%)
Nausea and vomiting— no. (%)	7 (58.0%)	6(60.0%)
Systolic blood pressure (mmHg)	125±13(120-155)	128±11(110-150)
— mean±sd (range)	/77±11(57-98)	/79±5(70-90)
Heart rate (beats/min) — mean±sd (range)	87±7(75-100)	83±12(59-101)
Partial pressure of oxygen (mmHg)	86±12 (58-93)	92±9 (76-96)
— mean±sd (range)		
<b>Laboratory values</b>		
WBC (10 <sup>9</sup> /L) — mean±sd (range)	6.84±3.07 (3.65-12.74)	5.19±0.72 (3.96-5.92)
Lymphocyte (10 <sup>9</sup> /L) — mean±sd (range)	1.11±0.61 (0.29-2.28)	1.00±0.49 (0.17-1.85)
D-dimer (mg/L) — mean±sd (range)	2.35±2.91 (0.19-6.84)	1.54±2.86 (0.17-8.43)
Increase in level of D-dimer — no. (%)	4 (33.3%)	2 (20.0%)
<b>Respiratory pathogens</b>		
The nucleic acid of COVID-19 — no. (%)	12(100.0%)	10(100.0%)
Unilateral pneumonia — no. (%)	0	0
Bilateral pneumonia — no. (%)	12(100.0%)	10(100.0%)
<b>Comorbidities</b>		
Diabetes mellitus — no. (%)	2(16.7%)	1(10.0%)
Cardiovascular disease — no. (%)	1(8.3%)	3(50.0%)
Cerebrovascular disease — no. (%)	1(8.3%)	1(10.0%)
<b>Treatment</b>		
Oxygen therapy — no. (%)	12(100.0%)	10(100.0%)
Mechanical ventilation — no. (%)	2(16.7%)	1(10.0%)
Antibiotic treatment — no. (%)	4(33.3%)	3(30.0%)
Antifungal treatment — no. (%)	0	0
Antiviral treatment — no. (%)	12(100.0%)	10(100.0%)
Glucocorticoids — no. (%)	12(100.0%)	10(100.0%)
Intravenous Ig therapy — no.(%)	2(16.7%)	2(20.0%)
<b>Clinical outcome</b>		
Remained in hospital — no. (%)	4 (33.3%)	7 (70.0%)
Discharged — no. (%)	7 (58.4%)	2 (20.0%)
Discharged for severe cases— no. (%)	3 (50.0%)	
Discharged for mild cases— no. (%)	4 (100%)	
Died — no. (%)	1 (8.3%)	1 (10.0%)

475

<b>Table 2. Clinical outcomes of 27 enrolled patients</b>			
	<b>Severity of illness — no. (%)</b>	<b>Outcomes (up to 2/26)</b>	<b>Total discharge — no. (%)</b>
<b>Dipyridamole group (n=12)</b>	Mild — 4 (33.3%)	4 discharged (100%)	7 (58.4%)
	Severe — 6 (50.0%)	3 discharged (50%) 2 in remission (33%)	
	Critical ill — 4 (33.3%)	1 in remission (50%) 1 death (2/09)	
<b>Control group (n=10)</b>	Mild — 4 (40.0%)	3 discharged (75%)	4 (40.0%)
	Severe — 4 (40.0%)	1 discharged (25%) 1 in remission (25%)	
	Critical ill — 2 (20.0%)	1 death (2/18)	

476

477

478

479

480

481

482

483

484

485

486


487

488

489

490

491 **Figures and Legends**



492

493 **Figure 1. Dipyridamole suppresses Mpro activity by the SPR assay.** Experimental SPR

494 sensorgram from Biacore 8K between dipyridamole (DIP) and Mpro, color points overlaid with a 1:1

495 Langmuir binding model kinetic fit (black). (A) Relative response from injection of DIP at 5, 10, 20,

496 40, 80, and 100 µM. Global analysis of the shape of the response curves yielded the parameters of

497 on-rate ( $K_{on} = 3.20E+3$ ), off-rate ( $K_{off} = 2.19E-1$ ) and the ratio of  $K_{off}$  divided by  $K_{on}$  ( $K_D = 68$  µM).


498 (B) Equilibrium binding responses plotted versus DIP concentration and fitted to a simple binding

499 isotherm to yield an affinity of 34 µM ( $K_{D,eq}$ ). (C) Suppressive effects of DIP and chloroquine on

500 HCoV-19 replication.  $P$  values were calculated by Student's  $t$  test.

501





502

503 **Figure 2. Dipyridamole (DIP) potentiates antiviral immunity to single-stranded RNA viruses. (A)**

504 Top, detection of *IFNB* and *IFIT1* mRNA expression in A549 cells treated with or without 5 μM DIP

505 followed by SeV or VSV infection. Middle, real-time PCR detection of *IFNB*, *ISG15* and *IFIT1*

506 mRNA expressions by A549 cells treated with different doses of DIP (0, 5 and 10 μM), followed by

507 intracellular poly (I:C) treatment. Bottom, ELISA detection of IFN-α production by A549 cells. (B)

508 Immunoblot detection of total and phosphorylated (p-) TBK1 and IRF3 in 293T cells with different

509 doses of DIP (0, 4, 20 μM), followed with or without SeV infection. (C) Schematic of the


510 VSV-infection mice model and the survival curve. (D) Histopathology of lungs from mice sacrificed

511 at Day4. Scale bars, 20 μm. Data in A are presented as the means ± SE of at least three biological

512 experiments. *P* values were calculated by Student's *t* test, \**P* < 0.05, \*\* *P* < 0.01, \*\*\* *P* < 0.001 and

513 \*\*\*\* *P* < 0.0001. Data in F are presented with 3 to 9 mice per group, *P* value was calculated by

514 Log-rank (Mantel-Cox) test (conservative).



515

516 **Figure 3. Changes of the study variables during the course of treatment. (A)** Dynamic changes

517 in the routine blood indexes (NEU, LYM, HGB, and PLT), coagulation variable (D-dimer), and

518 kidney function indices ( $\beta 2$ -MG) in reference to the baseline values. The levels of D-dimer were

519 sustained in DIP treatment group, while those in the control group were significantly increased.

520 Lymphocyte counts were persistently elevated in trend and PLT counts was significantly increased in

521 the DIP group in comparison to the control group. Data are shown as the means  $\pm$  SE across different



522 time bins during the treatment course.  $P$  values were calculated by Student's  $t$  test and indicated  
523 beside each panel. (B) Schematics of the treatment overview and clinical parameters of the deceased  
524 critically ill patient (top) and the surviving patient (bottom) who received DIP adjunctive therapy.


525

526

527

528

529



530

531 **Figure 4. Chest CT images in the axial (left panel) and coronal view (right panel) of**  
532 **represented severe COVID-19 patient before and after receiving DIP adjunctive therapy. (A)**  
533 **Initial chest CT scan 10 days before DIP treatment. (B) Chest CT scan 5 days before DIP treatment.**  
534 **(C) Chest CT scan 2 days before DIP treatment. (D) Chest CT scan 2 days after DIP treatment.**  
535 **(E) Chest CT scan 7 days after DIP treatment.**

536

537